The increasing speed of MRI and CT systems and their expanding vascular indications have made precision and reproducibility paramount considerations in contrast-enhanced studies. In mid-January, Nycomed Amersham locked in access to this technology,
The increasing speed of MRI and CT systems and their expanding vascular indications have made precision and reproducibility paramount considerations in contrast-enhanced studies. In mid-January, Nycomed Amersham locked in access to this technology, acquiring a sophisticated power injector system from Swiss-based manufacturer Bruker. Called Tomoject, this pump injector provides the constant and reliable flow of contrast media necessary for ultrafast imaging, including contrast-enhanced angiography, tumor diagnostics, organ perfusion, and incremental body imaging. Tomoject is currently marketed in Europe and other international venues. The manufacturing site will remain Zurich.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.